Nao Fujimori

Dr. Nao Fujimori

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2022 in European Journal of Cancer
Verified
Journal Article
Open access
MOMasato Ozaka
Masato Ozaka
KNKohei Nakachi
Kohei Nakachi
SKSatoshi Kobayashi
Satoshi Kobayashi
AOAkihiro Ohba
Akihiro Ohba
HIHiroshi Imaoka
Hiroshi Imaoka
JFJunji Furuse
Junji Furuse
We compared the efficacy of modified 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFIRINOX) with that of gemcitabine plus nab-paclitaxel (GnP) for locally advanced pancreatic cancer (LAPC). Patients with untreated LAPC were randomly assigned (1:1) to receive mFOLFIRINOX or GnP. One-year overall survival (OS) was the primary endpoint. The major secondary end-points included progression-free survival (PFS), response rate (RR), carbohydrate antigen 19-9 (CA19-9) response, and adverse events. The sample size was 124 patients to select a more effective regimen with a minimum probability of 0.85 and to examine the null hypothesis of the 1-year OS <53%. Of the 126 patients enrolled from 29 institutions, 125 were deemed eligible. The 1-year OS was 77.4% (95% CI, 64.9-86.0) and 82.5% (95% CI, 70.7-89.9) in the mFOLFIRINOX and GnP arms, respectively. The median PFS was 11.2 (95% CI, 9.9-15.9) and 9.4 months (95% CI, 7.4-12.8) in the mFOLFIRINOX and GnP arms, respectively. The RR and CA19-9 response rate were 30.9% (95% CI, 19.1-44.8) and 57.1% (95% CI, 41.0-72.3) and 42.1% (95% CI 29.1-55.9) and 85.0% (95% CI, 70.2-94.3) in the mFOLFIRINOX and GnP arms, respectively. Grade 3-4 diarrhoea and anorexia were predominant in the mFOLFIRINOX arm. GnP was considered the candidate for a subsequent phase III trial because of its better RR, CA19-9 response, and mild gastrointestinal toxicities. Both regimens displayed higher efficacy in the 1-year survival than in the historical data of gemcitabine monotherapy.

29 June 2022 in Digestive Endoscopy
Verified
Journal Article
Closed access
MKMasayuki Kitano
Masayuki Kitano
MYMakoto Yoshida
Makoto Yoshida
RAREIKO ASHIDA
REIKO ASHIDA
EKEmiri Kita
Emiri Kita
AKAkio Katanuma
Akio Katanuma
HYHiroki Yamaue
Hiroki Yamaue

19 January 2024 in Pancreatology
Verified
Journal Article
Closed access
TTTetsuya Takikawa
Tetsuya Takikawa
KKKazuhiro Kikuta
Kazuhiro Kikuta
TSTakanori Sano
Takanori Sano
TITsukasa Ikeura
Tsukasa Ikeura
NFNao Fujimori
Nao Fujimori
AKAtsuto Kayashima
Atsuto Kayashima

29 April 2024 in Journal of Gastroenterology
Verified
Journal Article
Open access
PDF file
KMKazuhide Matsumoto
Kazuhide Matsumoto
NFNao Fujimori
Nao Fujimori
KIKazuya Ichihara
Kazuya Ichihara
ATAyumu Takeno
Ayumu Takeno
MMMasatoshi Murakami
Masatoshi Murakami
YOYoshihiro Ogawa
Yoshihiro Ogawa
Background: Recently, two molecular subtypes of pancreatic ductal adenocarcinoma (PDAC) have been proposed: the “Classical” and “Basal-like” subtypes, with the former showing better clinical outcomes than the latter. However, the “molecular” classification has not been applied in real-world clinical practice. This study aimed to establish patient-derived organoids (PDOs) for PDAC and evaluate their application in subtype classification and clinical outcome prediction. Methods: We utilized tumor samples acquired through endoscopic ultrasound-guided fine-needle biopsy and established a PDO library for subsequent use in morphological assessments, RNA-seq analyses, and in vitro drug response assays. We also conducted a prospective clinical study to evaluate whether analysis using PDOs can predict treatment response and prognosis. Results: PDOs of PDAC were established at a high efficiency (> 70%) with at least 100,000 live cells. Morphologically, PDOs were classified as gland-like structures (GL type) and densely proliferating inside (DP type) less than 2 weeks after tissue sampling. RNA-seq analysis revealed that the “morphological” subtype (GL vs. DP) corresponded to the “molecular” subtype (“Classical” vs. “Basal-like”). The “morphological” classification predicted the clinical treatment response and prognosis; the median overall survival of patients with GL type was significantly longer than that with DP type (P < 0.005). The GL type showed a better response to gemcitabine than the DP type in vitro, whereas the drug response of the DP type was improved by the combination of ERK inhibitor and chloroquine. Conclusions: PDAC PDOs help in subtype determination and clinical outcome prediction, thereby facilitating the bench-to-bedside precision medicine for PDAC.

1 May 2014 in Pancreatology
Verified
Journal Article
Closed access
YNYusuke Niina
Yusuke Niina
TITetsuhide Ito
Tetsuhide Ito
TOTakamasa Oono
Takamasa Oono
TNTaichi Nakamura
Taichi Nakamura
NFNao Fujimori
Nao Fujimori
RTRyoichi Takayanagi
Ryoichi Takayanagi

10 June 2022 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
AOAkihisa Ohno
Akihisa Ohno
NFNao Fujimori
Nao Fujimori
TKToyoma Kaku
Toyoma Kaku
YTYu Takamatsu
Yu Takamatsu
KMKazuhide Matsumoto
Kazuhide Matsumoto
YOYoshihiro Ogawa
Yoshihiro Ogawa